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Cost-effectiveness of telehealth for patients with
depression: evidence from the Healthlines
randomised controlled trial
Padraig Dixon, Sandra Hollinghurst, Louisa Edwards, Clare Thomas, Alexis Foster, Ben Davies,
Daisy Gaunt, Alan A. Montgomery and Chris Salisbury
Background
Depression is a prevalent long-term condition that is associated
with substantial resource use. Telehealth may offer a cost-
effective means of supporting the management of people with
depression.
Aims
To investigate the cost-effectiveness of a telehealth
intervention (‘Healthlines’) for patients with depression.
Method
A prospective patient-level economic evaluation conducted
alongside a randomised controlled trial. Patients were recruited
through primary care, and the intervention was delivered via a
telehealth service. Participants with a confirmed diagnosis of
depression and PHQ-9 score $10 were recruited from
43 English general practices. A series of up to 10 scripted,
theory-led, telephone encounters with health information
advisers supported participants to effect a behaviour change,
use online resources, optimise medication and improve
adherence. The intervention was delivered alongside usual
care and was designed to support rather than duplicate
primary care. Cost-effectiveness from a combined health and
social care perspective was measured by net monetary benefit
at the end of 12 months of follow-up, calculated from
incremental cost and incremental quality-adjusted life years
(QALYs). Cost–consequence analysis included cost of lost
productivity, participant out-of-pocket expenditure and the
clinical outcome.
Results
A total of 609 participants were randomised – 307 to receive
the Healthlines intervention plus usual care and 302 to receive
usual care alone. Forty-five per cent of participants had
missing quality of life data, 41% had missing cost data and
51% of participants had missing data on either cost or utility,
or both. Multiple imputation was used for the base-case
analysis. The intervention was associated with incremental
mean per-patient National Health Service/personal social
services cost of £168 (95% CI £43 to £294) and an incremental
QALY gain of 0.001 (95% CI −0.023 to 0.026). The incremental
cost-effectiveness ratio was £132 630. Net monetary benefit at
a cost-effectiveness threshold of £20 000 was −£143 (95% CI −
£164 to −£122) and the probability of the intervention being
cost-effective at this threshold value was 0.30. Productivity
costs were higher in the intervention arm, but out-of-pocket
expenses were lower.
Conclusions
The Healthlines service was acceptable to patients as a
means of condition management, and response to treatment
after 4 months was higher for participants randomised
to the intervention. However, the positive average inter‐
vention effect size was modest, and incremental costs were
high relative to a small incremental QALY gain at 12 months.
The intervention is not likely to be cost-effective in its
current form.
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The management of long-term conditions is challenging. Some
30% of the population of England are estimated to have a long-
term condition,1 whereas their treatment constitutes 70% of all
health and care expenditure in England.1 Depression may be
considered as an exemplar long-term condition: it is prevalent,2
recurrent,3 associated with morbidity and comorbidity,4 mortality4
and substantial resource use.5
One form of care that may be relevant to the manage‐
ment of depression (and other long-term conditions) is telehealth.6
Telehealth can be defined as the use of technology to deliver
healthcare remotely and to promote patient self-management.7
A multicentre, parallel, two-arm, individually randomised con-
trolled trial (RCT) was undertaken to assess the effectiveness and
cost-effectiveness of a structured, theory-driven telehealth inter-
vention – ‘Healthlines’ – for patients with depression. This paper
describes the results of an economic evaluation conducted along-
side the RCT in order to estimate the cost-effectiveness of the
Healthlines service for primary care patients with depression.
Method
Patients with a confirmed diagnosis of depression, and a score
$10 on the validated8 and widely used9 nine-item Patient Health
Questionnaire (PHQ-9) depression scale10 were recruited from 43
general practices in or near the English cities of Bristol, Sheffield
and Southampton. The design of the telehealth intervention,11 the
protocol for the RCT12 and results of the RCT13,14 have been
reported elsewhere. In brief, 609 patients were individually
randomised to receive either usual care or usual care plus the
Healthlines service. Patients were followed up for 12 months.
The main perspective adopted for the economic evaluation, in
line with National Institute for Health and Care Excellence
(NICE) guidance,15 was that of the health and social care provider.
A cost-effectiveness analysis was carried out from this perspective
comparing costs, to the UK National Health Service (NHS) and
personal social services (PSS) sectors, with quality-adjusted life
years (QALYs). We also separately report the impact of the
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intervention on personal expenditure and on productivity as part
of a cost–consequence analysis.
Intervention
The Healthlines service was developed based on a programme of
work13 that encompassed a systematic review of effective telehealth
interventions,16 qualitative work on patient and provider experi-
ences of telehealth,17 a survey of patient attitudes toward tele-
health18 and reviews of evidence-based treatment guidelines for
depression. This work informed the development and delivery of
the de novo telehealth intervention11 delivered in the RCT.
The intervention consisted of telephone support designed to
encourage participants to use resources available from the
internet, along with efforts to optimise treatment and promote
medication adherence. Resources available included a self-directed
cognitive–behavioural therapy (CBT) course involving the use of a
book or the CBT website ‘Living Life to the Full Interactive’
(LLTTFi); access to a secure web portal which included health
information; access to the Big White Wall (BWW) online forum;
requests for discussions with the trial’s trained health information
advisors (HIAs – see below); and copies of letters sent to the
participant’s general practitioner (GP).
Scripted, scheduled telephone encounters took place over
the 12 months of trial follow-up between trial participants and
HIAs. The HIAs, non-clinical staff with experience in provid‐
ing health information to members of the public by telephone,
were provided with additional training in order to deliver the
Healthlines service. They were employed by the NHS, and they
received supervision from nursing staff and from pharmacists.
Participants randomised to the intervention were eligible to
receive a maximum of 10 such telephone-based encounters and
also receive usual care.
Participants randomised to the control arm received usual care
for depression.
Measurement of outcomes
The primary clinical outcome for the trial was the proportion of
patients responding to treatment at 4 months from randomisa-
tion, measured using the PHQ-9 questionnaire. Response was
defined as a reduction (from baseline) in PHQ-9 of at least 5
points and an overall score of less than 10. PHQ-9 responses were
also collected at 8 and 12 months.
Information on health-related quality of life was collected at
baseline, 4, 8 and 12 months using the EQ-5D-5L questionnaire,19
a standardised, generic instrument that allows for the measure-
ment and valuation of health-related quality of life. The EQ-5D-5L
measures five dimensions of health-related quality of life (mobi-
lity, self-care, usual activities, pain and discomfort, and anxiety
and depression) with five categories of health states corresponding
to no problems, slight problems, moderate problems, severe
problems and extreme problems. The EQ-5D-3L version of the
questionnaire is known to discriminate between different levels of
depression severity20 and has ‘adequate’ validity and responsive-
ness in patients with depression.21
Measurement and valuation of resource use
With participant consent, details of all primary care consultations
and relevant prescriptions (antidepressants, hypnotics and anxioly-
tics, and drugs used in psychoses and related disorders) issued during
the 12-month follow-up period were extracted from GP records.
Questionnaires administered at 4, 8 and 12 months requested
information on other healthcare and social care accessed for
reasons connected with the participant’s depression. This ques-
tionnaire, versions of which have been used in previous within-
trial primary care evaluations, is available from the ‘Database of
Instruments for Resource Use Measurement’ at www.dirum.org.
The questionnaire included the use of hospital services, attendance
at accident and emergency departments, ambulance use, and the
use of PSS such as social worker services. The questionnaires also
requested information on the use of private therapies, out-of-
pocket expenditure, time-off from work, benefits received, informal
care and the use of voluntary-sector services. The questionnaires
could be completed online or by post, but those completing them
online still had to complete the EQ-5D by post because of licencing
restrictions.
All resources were valued and costs reported in pound sterling
at 2012/13 prices. Curtis22 was used to cost primary care
consultations, community health and social care where possible.
NHS National Reference Costs for 2012/1323 were used to value
hospital and ambulance use. All sources are described in the
supplementary material (see in particular Tables DS1 and DS2).
The costs of drugs prescribed in primary care and reported in
medical records were based on the Prescription Cost Analysis
England database24 and cross-checked against the British National
Formulary. The value of personal expenditure was obtained
directly from participant responses to questionnaires.
Productivity costs were calculated from reports of working
days missed by trial participants, by friends and relatives as a
consequence of the participant’s depression, and time from work
to attend healthcare appointments. All of this time was valued at
the national median gross hourly wage of £11.59 for 2013.25
Data on the resources used to provide the Healthlines service
were extracted from provider computer systems. This included
the number and length of all telephone calls, the number of
attempts by a HIA to contact a participant, the use of the LLTTFi
website, the number of people who were sent the designated
CBT book, and the use of the BWW website. Resources involved
in establishing the service included training costs and the pur‐
chase of licences for LLTTFi and BWW, and these were included
in the calculation of intervention cost. Table DS3 in the online
supplementary material summarises the unit costs of these
resources.
The HIAs were remunerated at Band 4 of the NHS ‘Agenda
for Change’ pay scale. Cost-per-hour was estimated using the
framework of Curtis,22 adjusted to reflect the working pattern of
the HIAs. Anonymised task-scheduling diaries kept by the HIAs
were used to estimate the proportion of their time spent not in
contact with intervention participants: the ratio of contact/non-
contact time was estimated to be 2:1. Further adjustment was
made to allow for the 40-h workweek of the HIAs. HIAs received
initial and ongoing training from a nurse-grade trainer and from a
consultant psychiatrist in the LLTTFi package. The costs of
training were amortised over an assumed duration of 3 years.
This reflects the consideration that any training received would be
relevant to the service for at least 3 years, after which additional
training might become necessary. We regard this as a conservative
assumption.
Analysis of data
All analyses were conducted in Stata 13.1 (Statacorp: College
Station, Texas).
The distribution of all data used in the analysis was inspected
and summary measures such as means and standard deviations
calculated. The data were inspected for missingness. Data relating
to the use of the intervention and primary care data (including
prescriptions) were generally complete. Less than 0.5% of data
relating to primary care consultations were missing. These missing
values were imputed with mean values at the participant level. The
resulting data-set formed our ‘available cases’. The predominant
sources of any remaining missing data were questionnaire
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responses, particularly questions relating to resource use and
quality of life. In spite of satisfactory data completeness on
primary care and the intervention, missing questionnaire
responses meant that 45% of participants had missing quality of
life data, 41% had missing cost data, and 51% of participants had
missing data on either cost data or utility data, or both. Complete
cases had complete data on all cost items and all quality of life
data items at all time points, and 49% of participants (47% in the
intervention arm, 51% in the control arm) qualified as complete
cases under this definition.
Missing data were imputed using multiple imputation by
chained equations, as implemented by the – ice – command26,27 in
Stata 13.1. Data were assumed to be missing at random (MAR).
The imputation model was stratified by trial arm27 and included
demographic and cost variables without missing data alongside
clinical outcome variables at baseline and follow-up, cost and
utility variables with missing data, depression history, baseline
depression status and whether patients were being prescribed
antidepressants. Predictive mean matching was used to account
for non-normal distributions in some included variables.27 Passive
imputation was performed for categorical variables, such as binary
PHQ-9 scores, that were functions of imputed variables.
Costs were imputed at the level of the major aggregate costs
(e.g. primary care, medication, PSS costs and other NHS costs).
The number of imputations (n=60) was selected to be greater than
the proportion of missing data following White et al.27
Health-related quality of life utility measures at each follow-up
time point were imputed, which were then used to generate QALY
estimates. Utility values were calculated at baseline and the three
follow-up time points. These data were obtained from participant
responses to the EQ-5D-5L. We used the Euroqol UK crosswalk
value set for mapping responses to the three-level version of EQ-
5D.28 QALYs were calculated from the utility data using the ‘area
under-the-curve’ method and adjusted for baseline differences in
EQ-5D-5L scores.29
Cost-effectiveness analysis was performed on the imputed
dataset using the methods described in Faria et al,30 which
implement ‘Rubin’s rules’,31 in order to reflect the variation
within and between the 60 imputed data-sets. Regression analysis
was used to generate the cost-effectiveness results and to
characterise the uncertainty surrounding point estimates. See-
mingly unrelated regression (SUR) was used to jointly model costs
and QALYs using the – sureg – command in Stata. Baseline
imbalances in utility were controlled for in the regression model.32
Incremental cost-effectiveness ratios (ICERs) were calculated
from estimated coefficients. To avoid the complications33,34 of
calculating confidence intervals around ICERs, confidence inter-
vals are presented only for net benefit statistics, which were
calculated parametrically from regression output.35 Net monetary
benefit estimates were calculated using threshold values of £20 000
and £30 000 suggested by the NICE for use within NHS decision-
making.15 Costs and outcomes were not discounted as trial follow-
up was limited to 12 months. Analysis was conducted using an
‘intention to treat’ approach.
Sensitivity analysis
The base-case cost-effectiveness analysis used imputed data. As a
sensitivity check, cost-effectiveness was also estimated on com-
plete cases only and the results were compared. For both imputed
and complete case data, probabilistic sensitivity analysis was
implemented by calculating cost-effectiveness acceptability curves
(CEACs) to quantify uncertainty around point estimates of net
monetary benefit.
One-way sensitivity analysis was also performed. The sensi-
tivity of the imputed results to self-reported use of secondary care
was tested by removing these costs. Although all questionnaire
responses concerning secondary care use were checked by a
clinician for relevance to depression, the sensitivity analysis
provides a means of assessing whether recall bias, misclassification
or infrequent but expensive events differed between arms. The
sensitivity of the results to the cost of an element of the
intervention – that of the BWW licence – was also assessed in
order to account for the possibility that these licence costs would
be lower if the intervention were rolled out across the NHS.
Results
A total of 307 participants were randomised to receive the
intervention and 302 to the control arm. The mean age in the
control (intervention) arm was 50.0 (49.1) years; 68% (69%) were
female and 97% (98%) of participants were of White ethnicity.
The mean PHQ-9 score at baseline was 16.7 (17.1), 93% (91%) of
respondents had previously been treated for depression, and 90%
(87%) of participants were taking antidepressants at the time of
randomisation.
Resource use and cost
Twenty-six per cent of participants, of those known to have
received any calls, received none or little of the intervention
(defined as starting two or fewer telephone encounters), 44%
received some of the planned intervention sessions (3–8 encoun-
ters) and 29% of participants received all or almost all of the
intervention (9–10 encounters). The median number of encoun-
ters was 5 (interquartile range: 2 to 9), and the mean duration of
an encounter was 18.5 min.
The mean per participant cost of the intervention was £113, of
which costs associated with telephone encounter calls (such as
HIA remuneration and associated on-costs) comprised 66% of the
total (Table 1).
Patients in the intervention arm incurred more primary care
costs than did patients in the control arm, primarily because of a
greater number of GP consultations. Prescription costs were
Table 1 Mean (s.d.) depression intervention cost (£) per participant for all participants and complete cases
Intervention elements All intervention participants (n=308)a mean £ (s.d.) Complete cases (n=145)a mean £ (s.d.)
Encounter calls 71.84 (57.64) 86.55 (56.39)
Non-scheduled calls 3.26 (7.17) 3.58 (6.51)
All calls 75.11 (61.04) 90.13 (59.18)
LLTTFi website 9.74 (6.5) 12.18 (6.39)
ODLM book 9.09 (19.98) 9.45 (12.53)
Big White Wall 19.09 (12.75) 23.88 (12.53)
Total cost per participant 113.03 (80.46) 135.68 (77.93)
LLTTFi, Living Life to the Full Interactive online cognitive-behavioural therapy programme; ODLM, Overcoming Depression and Low Mood: A Five Areas Approach cognitive–behavioural
therapy book.36
a. Includes one usual care participant who received the intervention in part in error.
Dixon et al
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similar between arms. Intervention patients incurred higher
secondary care costs but lower PSS costs. We use imputed data
for our base-case results and because we imputed at the level of
aggregate cost categories rather than at the resource level, we
present these costs in Table 2. Detailed, disaggregated resource use
data on available and complete cases are presented in the
supplementary material in Tables DS4 to DS10.
Quality of life
The QALYs were calculated to adjust for baseline EQ-5D scores
(Table 3).The control arm baseline mean EQ-5D score was 0.52
(s.e.50.02) compared with an intervention baseline EQ-5D score
of 0.51 (s.e.50.02), calculated using the imputed data-set.
Cost-consequence results
Table 4 relates major cost categories to outcomes in a cost–
consequence matrix, using available data (i.e. before multiple
imputation of missing values).
NHS/PSS costs were significantly higher in the intervention
arm, largely owing to the cost of the intervention. Participants in
the control arm reported higher expenditure on private healthcare
costs such as private counselling, psychotherapy, psychiatry and
complementary/alternative remedies (mean per patient in avail-
able cases: £47.54) than in the intervention arm (mean per patient
in available cases: £39.28). Patients also reported slightly higher
expenditure in the control arm compared with the intervention
arm on out-of-pocket expenses connected with their condition
such as self-help books and gym memberships.
The value of lost production was approximately three times
higher in the intervention arm for the following reasons. Inter-
vention participants reported a greater number of days affected by
depression (mean per patient in available cases: 12.4 working days
(s.d.542.0) in the intervention arm compared with 5.2 working
days (s.d.515.7)) and more hours taken from work to attend
healthcare appointments (mean per patient in available cases:
12.8 h (s.d.586.8) in the intervention arm compared with 2.9 h
(s.d.512.5)).
These findings are influenced by a small number of indivi-
duals in the intervention arm who reported large amounts of lost
time, and hence these results are probably owing to chance
imbalance. No participant in the control arm reported more than
120 working days lost owing to depression, whereas 11 individuals
in the intervention arm had at least 120 working days lost, with a
mean value among this group of individuals of 187 days.
The consequences of the intervention include a significant
increase in the proportion of responders to treatment, correspond-
ing to a ‘number needed to treat’ of 12, and a reduction in mean
PHQ-9 scores of −0.5 (95% confidence interval −1.5 to 0.5).
Cost-effectiveness analysis
Base-case cost-effectiveness results, using imputed data, from the
perspective of a health and social care provider (i.e. NHS/PSS) are
presented in Table 5. Results from an NHS-only perspective
are presented in online supplementary material (Table DS11 and
Fig. DS1) and are similar.
The QALY difference between arms is small (1/1000th of a
QALY), equivalent to less than half a day in perfect health, and is
associated with incremental costs of £168. Figure 1 indicates the
probability that the intervention is cost-effective at different values
of the cost-effectiveness threshold. The intervention is not cost-
effective at the NICE thresholds of either £20 000 or £30 000.
Sensitivity analyses
The results are not sensitive to the exclusion of secondary NHS
costs. The effect of removing these costs is to slightly narrow the
difference in cost between arms relative to the base case, but to
leave the modest between-arm QALY difference unchanged. The
intervention was not cost-effective under this scenario (Table 6).
Two further deterministic sensitivity analyses were conducted
– one in which the cost of BWW licences was reduced by 50% and
another in which the cost of these licences was set to zero. These
changes had very minor effects on estimated net benefit and in
both cases the intervention was not cost-effective (results not
reported).
The cost-effectiveness analysis was re-run on complete cases
from an NHS/PSS perspective. In contrast to the analysis on
imputed data, this analysis suggested that the intervention is cost-
effective with a high probability (Table 7). The CEAC for the
complete case analysis is presented in the online supplementary
material (Fig. DS2).
Discussion
Analysis of the primary clinical endpoint indicated that the
intervention was effective when measured by the pre-specified
primary outcome of proportion of responders in each arm
measured by PHQ-9 scores at 4 months.14 This improvement is
less evident in the 12-month between-arm QALY comparisons
and therefore in the overall cost-effectiveness analyses. However,
any comparison between the primary clinical outcome and the
cost-effectiveness outcome must account for the differences
between the outcomes (proportion of responders measured using
PHQ-9 and cost-effectiveness using NHS/PSS costs and QALYs),
the different time periods over which the outcome is measured (at
4 months and over 12 months) and the overall effect size.
Table 2 Imputed NHS and PSS costs
Imputed costs Na Usual care mean £ (s.e.)b Intervention mean £ (s.e.)b
Imputed mean primary care costs 609 362 (15) 404 (17)
Imputed mean drug costs 609 88 (12) 92 (10)
Imputed mean hospital, ambulance and other non-primary care NHS costs 609 230 (34) 263 (37)
Imputed mean intervention cost 609 – 113 (5)
Imputed mean NHS costs, including the intervention 609 680 (41) 872 (46)
Imputed mean PSS costs 609 38 (13) 14 (5)
Imputed mean NHS and PSS costs, including the intervention 609 718 (45) 886 (47)
PSS, personal social services.
a. This sample size is based on 60 imputed datasets.
b. Standard errors – rather than standard deviations – are reported for imputed data.
Table 3 Imputed QALYs
Na
Usual care
mean (s.e.)
Intervention
mean (s.e.)
Imputed adjusted QALYs 609 0.540 (0.009) 0.541 (0.009)
QALYs = quality-adjusted life years.
a. This sample size is based on 60 imputed datasets.
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Three considerations are important in interpreting the small
between-arm QALY difference. The first is that these differences
are consistent with the modest mean effect size in analysis of the
intervention on the primary PHQ-9 clinical outcome and the
possibility that the intervention was helpful for some but not all
participants.14 Analysis of secondary trial outcomes indicated
greater improvements in anxiety, and greater satisfaction with
support, among those randomised to the intervention.14
The second consideration is that analysis of correlation (using
Spearman’s rho) indicates that high PHQ-9 scores (indicating
greater severity of depression) and low EQ-5D scores (indicating
lower quality of life) are correlated at baseline and all follow-
up time points. The null of independence was rejected in each
case (P<0.001), and the absolute value of the correlations were
largest with the anxiety/depression domain of the EQ-5D
instrument. This is tentative evidence that the two instruments
indicate the same ‘direction of travel’ for outcomes, and that
the lower sensitivity21 of the EQ-5D instrument used in the
QALY calculations is not as important to the analysis as the
finding that the intervention exerted a positive but modest
impact on depression and particularly on health-related quality
of life.
The third consideration relates to the amount of missing data.
Some 51% of participants had incomplete data on variables
necessary to conduct an inferential cost-effectiveness analysis.
This was in spite of near-complete data on primary care resource
use, prescriptions and intervention cost. Incomplete questionnaire
responses to questions on quality of life and NHS resource use
account for almost all of the missing data. This was largely
Table 4 Cost-consequence matrix (based on available cases)
Available data on costs and consequences Usual care N (usual care) Intervention N (intervention) Difference (95% CI)
Costs (£)
Mean cost of intervention 0‡ 188 136 169 –
Mean cost of NHS resources, excluding
cost of intervention
645 188 709 169 64 (−76 to 193)a
Mean cost of NHS resources, including intervention 646 188 845 169 199 (79 to 339)a
Mean cost of PSS 37 193 15 171 −21 (−73 to 1)a
Mean cost of NHS and PSS resources,
including intervention
683 188 860 169 177 (41 to 317)a
Out-of-pocket expenses 199 246 177 233 −21 (−116 to 57)a
Mean societal value per patient of
lost production
74 246 242 233 168 (45 to 362)a
Consequencesb
PHQ-9 response at 4 months, adjusted for
site and baseline PHQ-9
19% 270 27% 255 Odds ratio 1.7 (1.1 to 2.5)
Adjusted mean PHQ-9c 12.0 261 11.5 255 −0.5 (−1.5 to 0.5)
EQ-5D-5Ld 0.564 227 0.569 219 0.005 (−0.053 to 0.061)a
Adjusted QALYsd 0.536 175 0.567 158 0.031 (−0.022 to 0.0810)a
CI, confidence interval; PSS, personal social services; PHQ-9, Patient Health Questionnaire; QALYs, quality-adjusted life years. Costs are reported accurate to £1 and may not sum to
apparent totals owing to the effects of rounding.
‡ One participant in the control arm received elements of the intervention, the estimated cost of which was estimated to be £0.38.
a. Confidence interval calculated as accelerated and bias corrected interval from 1000 bootstrap replicates to account for the skewed distribution of costs.
b. Except where otherwise stated, all consequences were measured at 12 months, or over a period up to 12 months.
c. Measured as the adjusted mean difference in continuous PHQ-9 scores at 12 months.
d. Based on available data, and adjusted for baseline EQ-5D responses.
Table 5 Cost-effectiveness of the Healthlines intervention from an NHS/PSS perspective
Usual care mean Intervention mean Difference (95% CI)
Costs and QALYs
Total NHS and PSS costs £718 £886 £168 (£43 to £294)
QALYs 0.540 0.541 0.001 (−0.023 to 0.026)
Cost-effectiveness statistics
ICER: £132 630
Probability that intervention cost-effective at CE threshold of £20 000: 0.30
Probability that intervention cost-effective at CE threshold of £30 000: 0.37
NMB at threshold of £20 000 (95% confidence interval): −£143 (−£164 to −122)
CI, confidence interval; PSS, personal social services; QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; CE, cost-effectiveness; NMB, net monetary benefit.
We report confidence intervals for the point estimate of net benefit, but not for the ICER. Confidence intervals for the ICER can be both difficult to interpret34 and statistically
intractable.33 Instead, we place an emphasis throughout our analysis on net benefit. We present cost-effectiveness acceptability curves and confidence intervals around net benefit
to represent uncertainty in our cost-effectiveness results.
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Fig. 1 Cost-effectiveness acceptability curve from an NHS/PSS
perspective for imputed model.
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because of licencing restrictions imposed on the use of the EQ-5D
questionnaire, which had to be sent separately from the main
follow-up questionnaires, and had to be sent by post when most
outcomes were collected online.
The incremental costs of the intervention arm did not change
drastically between imputed cases, available cases and complete
cases, largely because of near-complete data on the intervention
(the major element of intervention arm costs) and on primary
care data. The estimated QALYs from the imputed dataset,
adjusting for baseline differences, differed by 0.001 between
groups, compared with 0.037 QALYs in complete cases. Below,
we explain why the complete case analysis is likely to be both
biased and inefficient.
Strengths
The Healthlines RCT was designed as a pragmatic, theory-based
intervention to support patients with a prevalent long-term
condition. To our knowledge, it is one of the largest RCTs
conducted of a complex intervention based on telehealth for
patients with depression. The design and implementation of the
intervention itself was the evidence-based culmination of a broad
body of work intended to support the development of a
responsive, flexible telehealth service.
This economic evaluation adds to the limited evidence base on
the cost-effectiveness of telehealth37 and internet interventions for
mental health.38 The economic evaluation was based on analysis
of extensive and detailed patient-level data and, unlike a number
of studies included in the systematic review of Mistry et al,37 was
conducted with reference to guidelines for best practice in
economic evaluation.39
Limitations
The amount of missing cost and quality of life data poses
challenges for the analysis and interpretation of results. We
attempted to moderate any undue influence of the specific
imputation model implemented by following recommended
practice in multiple imputation. We compared results of available,
complete and imputed cases to assess the reasonableness of the
outputs from the imputation model.
It is notable that there was a marked difference between the
results using imputed data or complete cases. Estimated NHS
costs are similar between complete, imputed and available cases.
Table 6 Sensitivity analysis: cost-effectiveness of the intervention from an NHS/PSS perspective, excluding non-primary-care-/non-
intervention-related costs, on imputed data
Usual care mean Intervention mean Difference (95% CI)
Costs and QALYs
Total NHS/PSS costs £488 £623 £135 (£70 to £199)
QALYs 0.540 0.541 0.001 (−0.023 to 0.026)
Cost-effectiveness statistics
ICER: £114 624
Probability that intervention cost-effective at CE threshold of £20 000: 0.33
Probability that intervention cost-effective at CE threshold of £30 000: 0.40
NMB at threshold of £20 000 (95% confidence interval): −£111 (−£132 to −91)
CI, confidence interval; PSS, personal social services; QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; CE, cost-effectiveness; NMB, net monetary benefit.
We report confidence intervals for the point estimate of net benefit, but not for the ICER. Confidence intervals for the ICER can be both difficult to interpret34 and statistically
intractable.33 Instead, we place an emphasis throughout our analysis on net benefit. We present cost-effectiveness acceptability curves and confidence intervals around net benefit
to represent uncertainty in our cost-effectiveness results.
Table 7 Cost-effectiveness complete case from an NHS/PSS perspective in the depression trial
Usual care mean (n=155) Intervention mean (n=144) Difference (95% CI)
Costs and QALYs
Total NHS/PSS costs – complete case £719 £864 £145 (−£11 to £300)
QALYs – complete case 0.535 0.573 0.037 (0.009 to 0.066)
Cost-effectiveness statistics
ICER: £3850
Probability that intervention cost-effective at CE threshold of £20 000: 0.98
Probability that intervention cost-effective at CE threshold of £30 000: 0.99
NMB at threshold of 20 000 (95% Confidence interval): £607 (£572 to 642)
CI, confidence interval; QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; CE, cost-effectiveness; NMB, net monetary benefit.
We report confidence intervals for the point estimate of net benefit, but not for the ICER. Confidence intervals for the ICER can be both difficult to interpret34 and statistically
intractable.33 Instead, we place an emphasis throughout our analysis on net benefit. We present cost-effectiveness acceptability curves and confidence intervals around net benefit
to represent uncertainty in our cost-effectiveness results.
Table 8 Quality of life (EQ-5D) data in available, complete and
non-complete cases
Usual care Intervention
Quality of life Mean N Mean N
Baseline
All available data 0.52 268 0.51 273
Complete cases 0.52 155 0.54 144
Non-complete casesa 0.53 113 0.49 129
4-month follow-up
All available data 0.53 233 0.56 220
Complete cases 0.52 155 0.59 144
Non-complete casesa 0.56 78 0.50 76
8-month follow-up
All available data 0.54 227 0.56 210
Complete cases 0.53 155 0.59 144
Non-complete casesa 0.57 72 0.48 66
12-month follow-up
All available data 0.57 225 0.57 218
Complete cases 0.56 155 0.58 144
Non-complete casesa 0.60 70 0.56 74
a. Non-complete cases in this table refer to participants who did not have complete
EQ-5D data at all time points. The number of available observations at each time point
is therefore the sum of complete and non-complete cases.
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The pattern of missing EQ-5D data between different cases is
summarised in Table 8.
Complete case analysis is likely to be inefficient because it
would discard data from half of all trial participants. This analysis
would be biased because missingness in quality of life data seems
to be conditional on observed allocation to the intervention arm,
since participants in the intervention who did not provide data at
all time points had, on average, lower quality of life than those
who provided complete data (Table 8). In the control group, the
reverse is true: non-responders to the questionnaires had, on
average, a higher quality of life than the complete cases. Table 8
suggests a mechanism for the complete and imputed QALYs to
differ.
The amount of missingness in quality of life data complicates
comparisons with other trials. For example, the economic evalua-
tion40 of the CADET primary care trial of collaborative care,41
involving structured and scheduled patient follow-ups and
enhanced communication between medical professionals, deter-
mined that the intervention was likely to be cost-effective. An
important difference between the studies is the amount of missing
data in each trial, with CADET reporting missingness of up to
25% compared with 51% in Healthlines.
The level of adherence to the intervention is another poten‐
tial limitation. The median number of telephone encounters
known to have been initiated was 5, out of a total of 10 sche‐
duled encounters, although a focus on the number of com‐
pleted telephone encounters does not reflect all aspects of
compliance with the intervention. There is a lack of metho‐
dological guidance concerning how adherence should be
reflected in economic evaluation,42 albeit the focus on actual
adherence in the base-case analysis reflects the pragmatic design
of the trial. A complier-average causal effect analysis, using
the principal stratification method, of the main trial results13
suggested greater effectiveness among participants who received
more telephone encounters, although this did not account for
baseline variables.
Other limitations include the trial follow-up period, which was
limited to 12 months. Longer-term follow-up would be necessary
to establish persistence of effect and whether ongoing versus time-
limited telehealth support would be most appropriate for this
patient group.
It is not clear how closely the operation of the Healthlines
service would reflect a system-wide implementation. In practice,
scale effects and alternative rostering of HIAs and scheduling of
calls may secure more efficient operation, although there is no
evidence from the trial itself to indicate that substantial efficiency
improvements were available but left unexploited.
In order for the intervention to be cost-effective, it is likely
that it would need to be more effective rather than less costly.
Holding incremental costs constant, and ignoring the effects of
uncertainty, the threshold incremental QALY difference necessary
to result in an ICER<£20 000 is approximately 0.085 or about
eight times the effect size actually observed in the trial. Improving
the effectiveness of the intervention is likely to require better
targeting of the intervention to those interested in using it, efforts
to improve patient engagement and more effective optimisation of
anti-depressant medication when patients fail to respond to
treatment.14
In conclusion, the Healthlines service was found to be
acceptable to patients as a means of condition management,18
and response to treatment after 4 months was higher for
participants randomised to the intervention.14 However, the
intervention was associated with a small incremental QALY gain
at 12 months and was not likely to be cost-effective at a threshold
value of £20 000.
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